Fagron N.V. (ARSUF) Stock

About Fagron N.V.

Fagron N.V. is a specialized pharmaceutical compounding firm focused on delivering tailored medicinal solutions. The company caters to a diverse range of clients, including hospitals, pharmacies, clinics, and individual patients. Beyond providing direct services, Fagron N.V. actively drives innovation by developing cutting-edge concepts, delivery methods, and specific formulations for pharmaceutical compounding. Its extensive product line includes essential raw materials, specialized tools and equipment, semi-finished goods, various drug vehicles, and both sterile and non-sterile custom-prepared medications. Furthermore, the company supports professional development through the Fagron Academy, offering comprehensive education and training programs for medical prescribers and pharmacists. With a significant global presence, Fagron N.V. operates across Latin America, North America, Europe, the Middle East, and Africa. Founded in 1990 and headquartered in Nazareth, Belgium, the company underwent a name change in January 2015, rebranding from its former identity, Arseus N.V., to Fagron N.V.

Fagron N.V. is headquartered in BE.

Fagron N.V. (ARSUF) stock trades at $26.53 with a market capitalization of $1.95B. The stock is valued at a price-to-earnings (P/E) ratio of 19.10, price-to-book of 3.15, price-to-sales of 1.83. Over the past 52 weeks the stock has ranged between $23.50 and $27.00, and currently trades 1.7% below its 52-week high. It pays a dividend yielding 1.73%.

On profitability, Fagron N.V. generates a return on equity (ROE) of 17.29%, above the typical market average, return on capital employed of 14.41%, an operating margin of 15.50%, a net profit margin of 9.56%.

Official website: www.fagron.com